Multiple Myeloma Frontline Horizon: Quads, Bispecifics, and Breakthroughs

EP: 1.Unmet Needs In Multiple Myeloma Management

EP: 2.Evolving Goals in Multiple Myeloma Treatment

EP: 3.Multiple Myeloma Induction Challenges and Future Options

EP: 4.Optimizing Multiple Myeloma Treatment: Quadruplet Therapy

EP: 5.Real-World Insights: Multiple Myeloma Treatment Challenges

EP: 6.Navigating the Multiple Myeloma Treatment Landscape

EP: 7.Real-world Multiple Myeloma Treatment: Insights and Challenges

EP: 8.The Future of Multiple Myeloma Treatment

EP: 9.ASH 2023: Multiple Myeloma's Shifting Landscape: Trials and Clinical Perspectives

Now Viewing

EP: 10.Multiple Myeloma Frontline Horizon: Quads, Bispecifics, and Breakthroughs

This is a video synopsis/summary of a Peer Exchange featuring Joshua Richter, MD; Rafat Abonour, MD; Faith Davies, MD; and Amrita Krishnan, MD.

The panel discusses the future of multiple myeloma treatment, envisioning significant changes in the next 3 years. Krishnan emphasizes the importance of treatment discontinuation and the early use of bi-specifics, especially with upcoming trials such as CARTITUDE-6 (NCT05257083). Abonour reflects on the remarkable progress in myeloma treatment over the past 20 years and predicts a shift from proteasome inhibitors to bispecific T cell–directed therapy in upfront settings. Davies highlights the significance of deep responses, long progression-free survival, and the blurring line between transplant-eligible and noneligible patients. Richter anticipates the decline of quadruplet therapies and explores the potential of intentionally curing more patients through tailored approaches and treatment discontinuation.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.